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Two types of cohort studies examining patients infect-
ed with methicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant enterococci (VRE) were
contrasted, using different reference groups. Cases were
compared to uninfected patients and patients infected with
the corresponding, susceptible organism. VRE and MRSA
were associated with adverse outcomes. The effect was
greater when uninfected control patients were used.
A
lthough several investigators have performed out-
comes studies of patients infected or colonized with
antimicrobial resistant bacteria, the design and interpreta-
tion of results with various methods has not been discussed
(1). Typically, these outcomes studies use a cohort design
and study patients infected with resistant bacteria (the
exposure of interest for cases), who are compared either to
patients without infection selected from a similar popula-
tion (2–6) or to patients infected with corresponding, sus-
ceptible bacteria (e.g., comparing patients with
methicillin-resistant  Staphylococcus aureus [MRSA] to
patients with methicillin-susceptible S. aureus [MSSA])
(7–13) (Online Appendix, available at http://www.
cdc.gov/ncidod/eid/vol10no6/02-0665_app.htm). When
cases are compared to an uninfected reference group or
“control group,” the effect of a new, antimicrobial-resistant
bacterial infection is assessed. When case-patients are
compared to reference patients or “controls” infected with
the corresponding susceptible bacteria, the impact of
acquiring a resistance determinant is measured. Both types
of comparison are valid and important, but they address
different clinical scenarios. 
We examined how the choice of the reference group
might influence results of outcomes studies pertaining to
antimicrobial resistant bacteria. We compared and con-
trasted the results of outcomes cohort studies for resistant
bacteria by using the two different reference groups
discussed previously. We used results from original studies
of MRSA and vancomycin-resistant enterococci (VRE)
(9,10) that initially used one reference group. In our study,
we performed additional analyses comparing case-patients
to different reference patients and contrasted the results. 
The Study
Both MRSA and VRE studies were designed as cohort
studies and are discussed in detail elsewhere (9,10)
(Online Appendix). Cases were defined as patients with
MRSA surgical site infection (SSI) (i.e., the exposure of
interest for study 1) and VRE wound infection (i.e., the
exposure of interest for study 2). In each study, two differ-
ent reference groups were used in separate analyses.
Control group A included patients who did not have an
infection caused by the target pathogen (S. aureus or ente-
rococci). Control group B included patients with infection
caused by the susceptible phenotype of the target pathogen
(i.e., MSSA and vancomycin-susceptible enterococci
[VSE]).
In both studies, three outcomes were examined: death,
length of hospital stay, and total hospital charges. Hospital
charges were variable direct charges obtained from hospi-
tal financial databases and are a surrogate for cost.
Hospital costs were estimated using a cost-to-charge ratio
of 0.7 (14).
Outcomes studies of antimicrobial drug resistance are
notoriously hard to perform because of confounding vari-
ables related to underlying coexisting conditions (1). To
control for confounding, we analyzed several variables,
including individual coexisting conditions, the Charlson
score, the American Society of Anesthesiologists-Physical
Status (ASA) score, and duration of hospitalization before
infection (Online Appendix). These variables were ana-
lyzed in multivariable analysis. Each of the outcomes was
analyzed independently. The inverse log value was calcu-
lated for β coefficients of variables included in the predic-
tor models, and these effect measures were described as
the odds ratio (OR) for death rate and the multiplicative
effects (ME) on length of stay and charges. 
In the analysis comparing patients with SSI caused by
MRSA to uninfected controls, the study cohort included
314 patients: 121 MRSASSI cases and 193 uninfected sur-
gical controls (Online Appendix). In multivariable analy-
sis, MRSA SSI was significantly associated with death
(OR = 11.4, p < 0.001). In the analysis comparing patients
with MRSASSI to patients with SSI caused by MSSA, the
same 121 MRSAcase-patients were compared to 165 con-
trol-patients with MSSA SSI. In multivariable analysis,
MRSA SSI was significantly associated with death (OR =
3.4, p = 0.003). Additional covariates included in the
adjusted models for death are listed in the footnotes of
Table 1 and are discussed in the Online Appendix. The
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greater for the analysis using uninfected controls than for
the analysis using MSSA controls.
In the analysis comparing patients with SSI caused by
MRSA to uninfected controls, multivariable modeling
demonstrated that MRSA SSI was significantly associated
with an increased length of stay (ME = 3.2, p < 0.001).
Having an MRSA SSI was associated with an average
adjusted attributable increase of 13.4 hospital days per
case. In the analysis comparing patients with MRSASSI to
controls with SSI due to MSSA, a trend was seen toward
an association between MRSA SSI and total hospital days
(ME = 1.20, p = 0.11). Methicillin resistance was associat-
ed with an average adjusted attributable increase of 2.6
days per case, although this did not reach statistical signif-
icance. Additional covariates included in the adjusted
models for length of stay are listed in the footnotes of
Table 1 and are discussed in the Online Appendix. The
effect of MRSAon length of stay was approximately three-
fold greater (11 days) for the analysis using uninfected
controls than for analysis B using MSSA controls. 
In the analysis comparing patients with SSI due to
MRSA to uninfected controls, multivariable modeling
showed that MRSA SSI was significantly associated with
increased hospital charges (ME = 2.2, p < 0.001). MRSA
was associated with mean adjusted additional attributable
charges of $41,274 per case and an attributable cost of
$28,891 per case. In the analysis comparing patients with
SSI due to MRSA to controls with SSI due to MSSA,
MRSA was significantly associated with increased hospi-
tal charges (ME = 1.2, p = 0.03). Methicillin resistance
was associated with mean adjusted additional attributable
charges of $13,901 per MRSA SSI case and an attributa-
ble cost of $9,731 per case. Additional covariates includ-
ed in the adjusted models for cost are listed in the
footnotes of Table 1 and are discussed in the Online
Appendix. The effect of MRSA on cost was approximately
twofold greater ($15,000) for the analysis using uninfect-
ed controls than for the analysis using controls with SSI
due to MSSA. 
In the analysis comparing patients with wound infec-
tion due to VRE to uninfected controls, 99 patients with
VRE wound infection were compared to 280 matched con-
trols who were not infected with enterococci (Online
Appendix). In adjusted analysis, VRE wound infection
was not an independent predictor of deaths (OR 2.0,
p = 0.13). In the analysis comparing patients with wound
infection due to VRE to control patients with wound infec-
tion due to VSE, the same 99 VRE wound infection cases
were compared to 213 control patients with VSE wound
infections. In multivariable analysis, VRE was significant-
ly associated with mortality (OR 2.5, p = 0.04). Additional
covariates included in the adjusted models for death rates
are listed in the footnotes of Table 2 and are discussed in
the Online Appendix. The magnitude of effect of VRE on
deaths was similar for both analyses.
In the analysis comparing patients with wound infec-
tion due to VRE to uninfected controls, multivariable mod-
eling showed a significantly longer duration of
hospitalization after inclusion in the cohort for VRE cases
than for controls not infected with enterococci (ME 1.8,
p < 0.001, average adjusted attributable increase of 6.2
days in length of stay). In the analysis comparing patients
with wound infection due to VRE to control patients with
VSE wound infection, length of stay after isolation of ente-
rococci was similar among VRE cases and VSE controls
(mean of 15.2 vs. 13.6 days, p = 0.5) and the differences in
length of stay remained non-significant in multivariate
analysis (ME = 1.0, p = 0.5). Additional covariates includ-
ed in the adjusted models for length of stay are listed in the
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Table 1. Outcomes and adjusted analyses for MRSA for study 1
a 
Adjusted analyses 
Outcome  Cases  Controls  OR (95% CI)
b 
Attributable to 
MRSA  p value 
Three analyses comparing patients MRSA cases  
(n = 121) and uninfected controls (n = 193) 
         
Deaths  20.7%  2.1%  11.4 (2.8 to 34.9)
c  –  < 0.001 
Hospital days after surgery, mean per case   29.1  6.1  3.2 (2.7 to 3.7)
d  13.4  < 0.001 
Charges ($), mean/case  118,414  34,395  2.2 (2.0 to 2.6)
e  41,274  < 0.001 
Three analyses comparing MRSA cases  
(n = 121) and MSSA controls (n = 165) 
(n = 121)         
Deaths  20.7%  6.7%  3.4
f  –  0.003 
Hospital days after infection, mean per case  22.0  13.2  1.2
g  2.6  0.11 
Charges ($), mean per case  118,414  73,165  1.2
h  13,901  0.03 
aOR, odds ratio; CI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus. 
bOdds ratio for deaths, and multiplicative effect (ME) for continuous outcomes (length of stay and charges). 
cAdjusted for American Society of Anesthesiologists-Physical Status (ASA) score >3 and age. 
dAdjusted for ASA score, duration of surgery, hospital, renal disease, diabetes, and length of hospital stay before surgery.
 
eAdjusted for ASA score, hospital, duration of surgery, renal disease, length of hospital stay, and intensive care unit (ICU) stay before surgery. 
 
fAdjusted for ASA score >3, duration of surgery, and age.  
gAdjusted for ASA score, renal disease, diabetes mellitus, hospital, duration of surgery, and length of stay before infection.  
hAdjusted for ASA score, duration of surgery, length of hospital and ICU stay before infection, hospital, renal disease, and diabetes. footnotes of Table 2 and are discussed in the Online
Appendix. The effect of VRE on length of stay was
approximately twofold greater (6 days) for the analysis
using uninfected controls than for the analysis that used
VSE controls.
In the analysis comparing patients with wound infec-
tion due to VRE to uninfected controls, multivariable mod-
eling demonstrated that VRE cases generated significantly
greater hospital charges than controls (adjusted ME = 1.5,
p < 0.001, mean adjusted additional attributable charges of
$13,884 per VRE wound infection and attributable cost of
$9,719 per infection). In the analysis comparing patients
with wound infection due to VRE to controls with VSE
wound infection, VRE wound infection was associated
with increased hospital charges (ME = 1.4, p < 0.001, aver-
age adjusted additional attributable charges of $12,766 per
infection and attributable cost of $8,936 per infection).
Additional covariates included in the adjusted models for
cost are listed in the footnotes of Table 2 and are discussed
in the Online Appendix. The effect of VRE on cost was
similar in both analyses.
Conclusions
We examined how the criteria used to select a reference
group (i.e., a comparison or control group for cases) influ-
enced outcomes study results. Two types of control
patients were studied, and in both types of analyses, VRE
and MRSA were associated with significant, adverse clin-
ical outcomes. In general, the effects (i.e., OR or ME) were
of greater magnitude when controls not infected with the
target organism (and thus representative of a random sam-
ple of the source population) were used. This is logical
since analyses using uninfected controls assess the effect
of acquiring a new infection and a resistant pathogen.
When patients who are infected with a susceptible organ-
ism are used as controls, the analysis quantifies only the
effect of acquiring a resistance trait.
The differences in results between the two analyses
were much greater for the MRSA SSI study than for the
VRE wound infection study. The impact on clinical out-
comes was two- to threefold greater when patients with
MRSA SSI were compared to an uninfected control group
as opposed to comparison with control patients infected
with MSSA SSI. In contrast, when patients with VRE
wound infection were compared to uninfected patients,
similar results were obtained as when patients with VSE
wound infections were used as controls. We believe that
the magnitude of differences in results for the two analyses
is directly related to the virulence of the infecting organism
(Online Appendix).
The studies were performed in two different geograph-
ic locales and by using slightly different analytic methods.
While this is a limitation in that cost results are not direct-
ly comparable, we feel including these two studies
improves the generalizability of our results and strength-
ens our findings. 
For studies of antimicrobial resistance, a reference
group must be chosen on the basis of the investigators’
objective. From a public health perspective, results from
outcomes studies pertaining to antimicrobial resistance are
frequently used to help allocate resources for interven-
tions. If the objective of a study is to investigate the inde-
pendent effects of a resistance trait or phenotype (e.g.,
methicillin resistance), then the most appropriate control
group would consist of patients infected with a susceptible
corresponding organism. If the goal is to assess the effect
of a new infection caused by a particular pathogen, unin-
fected control patients would be the preferable comparison
group. Alternatively, a complete analysis might include
both types of control groups; this analysis would allow the
Antibiotic Resistance Outcomes
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Table 2. Outcomes and adjusted analyses for vancomycin-resistant enterococci (VRE) in study 2 
Adjusted analyses 
Outcome  Cases  Controls  OR
a  Attributable to VRE  p value 
Three analyses comparing VRE patients (n = 99) and 
uninfected controls (n = 280) 
         
Deaths  12.1%  6.1%  2.0
b  –  0.13 
Length of stay (d), mean per case  15.2  8.5  1.8
c  6.2  <0.001 
Charges ($), mean per case  46,660  27,224  1.5
d  13,884  <0.001 
Three analyses comparing VRE patients (n = 99) and 
vancomycin-susceptible enterococci (VSE) controls (n = 213) 
         
Deaths  12.1%  6.6%  2.5
e  –  0.04 
Length of stay (d), mean per case  15.2  13.6  1.0
f  –  0.5 
Charges ($), mean per case  46,600  31,915  1.4
g  12,766  <0.001 
aOdds ratio for deaths, and multiplicative effect (ME) for continuous outcomes (length of stay and charges). 
bAdjusted for number of comorbid illnesses and admission to the intensive care unit (ICU). 
cAdjusted for propensity score (i.e., likelihood of being a VRE case [Online Appendix]), being transferred from another institution, renal disease, 
malignancy, and admission to the ICU. 
dAdjusted for propensity score (i.e., likelihood of being a VRE patient), having had surgery before cohort inclusion, and duration of hospitalization before 
cohort inclusion. 
eAdjusted for surgery, sex, and admission to the ICU. 
fAdjusted for duration of hospitalization before cohort inclusion, admission to the ICU, and malignancy. 
gAdjusted for having had surgery before inclusion in the cohort, and duration of hospitalization before cohort inclusion. reader to assess the effect of acquiring a resistance pheno-
type alone and the impact of acquiring a new infection
caused by a resistant bacteria. 
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